ApprovalTrail

Drug · DIN 02459418

REVLIMID

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since November 22, 2024; first marketed December 20, 2016.
Drug Identification Number (DIN)
02459418
Company (DIN owner)
Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
Schedule
Prescription
Dosage form
Capsule
Route
Oral
Therapeutic class (ATC)
Lenalidomide L04AX04
Class
Human
Record last updated
March 22, 2025

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
LENALIDOMIDE2.5 MG

Notices of Compliance

Health Canada approvals that name this DIN.

  • February 9, 2024: NOC 32672New Drug Submission (NDS) · Administrative: Change in Product Ownership
  • December 14, 2016: NOC 18770Supplement to a New Drug Submission (SNDS) · Expansion to indication: in combination with dexamethasone is indicated for the treatment of multiple myelomw patients who are not eligible for stem cell trasplant. new strength 2.5 mg

Other DINs named REVLIMID